Blast­ing 'spec­u­la­tive com­men­tary,' GSK of­fers up­date on Zan­tac lit­i­ga­tion and vows to 'vig­or­ous­ly de­fend it­self'

GSK wants to ad­dress “spec­u­la­tive com­men­tary” about its Zan­tac lit­i­ga­tion head on.

The phar­ma gi­ant put out a lengthy state­ment af­ter a suite of an­a­lysts sound­ed the alarm on the po­ten­tial im­pact of the on­go­ing per­son­al in­jury law­suits, which trig­gered big plunges for its stock as well as that of its con­sumer health spin­out, Ha­le­on, and Sanofi, which al­so sold the drug at one point.

Zan­tac, a well-known drug used to re­duce stom­ach acid pro­duc­tion, was re­called glob­al­ly back in 2019 over “un­ac­cept­able lev­els of N-ni­troso­di­methy­lamine,” a car­cino­gen al­so known as ND­MA for short. The fol­low­ing year, the FDA and EMA rec­om­mend­ed that all prod­ucts con­tain­ing the ac­tive in­gre­di­ent ran­i­ti­dine be with­drawn.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER